Scholars Central

Research articlePublished 3 May 2019

Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patients

Authors: Geeta Yadav, Piyush Kumar

Der Pharma Chemica

Volume 10 · Issue 4 · Pages 11–18

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Undeterred efforts have been made and will be made in future to make it possible for HIV-infected individuals to achieve the goals of virologic suppression and one more addition to this rigorous exercise is dolutegravir drug. It is a recent integrase inhibitor approved by the United States of Food and Drug Administration (USFDA) for use in the treatment-naïve and treatment-experienced HIV-infected patients. This article has reviewed all the aspects of drug including the structural and functional analyses, in vitro activity, pharmacokinetics, drug-drug interactions, MOA, metabolism, excretion, dosing/adverse effects and resistance profile. Dolutegravir is a potent and well tolerated antiretroviral agent that may play an important role in the treatment of patients harboring resistance to other antiretrovirals. Some new combinations of drug with other antiretrovirals are also in pipeline which may hope to increase the immunologic response of the HIV patients.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Der Pharma Chemica.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDer Pharma Chemica
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Geeta Yadav”
  • BylineArticles whose byline prints “Piyush Kumar”